• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications.
【24h】

Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications.

机译：阿达木单抗用于治疗免疫介导的疾病：旧和最近适应症的更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ongoing progress in understanding the pathogenic mechanisms regulating various immune-mediated and inflammatory diseases, as well as the availability of innovative biotechnological approaches, have lead to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-alpha inhibitors such as infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. Adalimumab is a fully recombinant human immunoglobulin G1 monoclonal antibody that specifically binds with high affinity to human TNF-alpha and inhibits its binding to TNF receptors. Adalimumab was approved by the U.S. FDA in 2002 and was granted approval from the European Medicines Agency in September 2003 for the treatment of moderate to severe rheumatoid arthritis and subsequently for the treatment of ankylosing spondylitis, chronic plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and Crohn's disease. In this paper, we will briefly review the structure and biological effects of TNF-alpha, the old and recent indications of adalimumab, the pretreatment considerations, the reported adverse events and finally, the recommendations for its use in pregnancy.
机译：在理解调节各种免疫介导的和炎性疾病的致病机制方面的不断进步，以及可获得的创新生物技术方法，已导致开发了添加到常规治疗方法中的新药物。其中，肿瘤坏死因子（TNF）-α抑制剂，例如英夫利昔单抗，阿达木单抗，依那西普，戈利木单抗和塞妥珠单抗聚乙二醇化，现已可用于临床。阿达木单抗是一种完全重组的人免疫球蛋白G1单克隆抗体，可与人TNF-α高亲和力特异性结合并抑制其与TNF受体的结合。阿达木单抗于2002年获得美国FDA的批准，并于2003年9月获得欧洲药品管理局的批准，用于治疗中度至重度类风湿性关节炎，随后用于治疗强直性脊柱炎，慢性斑块状牛皮癣，银屑病关节炎，幼年特发性关节炎和克罗恩病。在本文中，我们将简要回顾TNF-α的结构和生物学作用，阿达木单抗的古老和近期适应症，治疗前的考虑因素，报道的不良事件以及最后有关在妊娠中使用的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号